Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine

Abstract

Yellow fever vaccines are routinely assayed by plaque assay. However, the results of these assays are then converted into mouse LD 50 using correlations/conversion factors which, in many cases, were established many years ago. The minimum required potency in WHO Recommendations is 10 3 LD 50/dose. Thirteen participants from 8 countries participated in a collaborative study whose aim was to assess the suitability of two candidate preparations to serve as an International Standard for yellow fever vaccine. In addition, the study investigated the relationship between the mouse LD 50 test and plaque forming units with a view to updating the WHO recommendations. Plaque assays were more reproducible than mouse assays, as expected. Differences in sensitivities of plaque assays were observed between laboratories but these differences appear to be consistent within a laboratory for all samples and the expression of potency relative to the candidate standard vaccine improved the reproducibility of assays between laboratories. However, the use of potencies had little effect on the between laboratory variability in mouse LD 50 assays. There appears to be a consistent relationship between overall mean LD 50 and plaques titre for all study preparations other than sample E. The slope of the correlation curve is >1 and it would appear that 10 3 LD 50 is approximately equivalent to 10 4 plaque forming units (PFU), based on the overall means of all laboratory results. The First International Standard for yellow fever vaccine, NIBSC Code 99/616, has been established as the First International Standard for yellow fever vaccine by the Expert Committee of Biological Standards of the World Health Organisation. The International Standard has been arbitrarily assigned a potency of 10 4.5 International Units (IU) per ampoule. Manufacturers and National Control Laboratories are including the First International Standard for yellow fever vaccine in routine assays so that the minimum potency in IU of vaccines released for use and which meet the current minimum potency of 10 3 LD 50 in mouse assays, can be determined. These data will be analysed before a review of the WHO requirements, including the minimum potency per dose, is undertaken.